A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice

Akira Kodama, University of Ryukyus
Reiko Tanaka, University of Ryukyus
Mineki Saito, Kawasaki Medical School
Aftab A Ansari, Emory University
Yuetsu Tanaka, University of Ryukyus

Journal Title: Frontiers in Microbiology
Volume: Volume 4, Number SEP
Publisher: Frontiers Media | 2013-09-27, Pages 292-292
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.3389/fmicb.2013.00292
Permanent URL: https://pid.emory.edu/ark:/25593/s73v1

Final published version: http://dx.doi.org/10.3389/fmicb.2013.00292

Copyright information:
© Kodama, Tanaka, Saito, Ansari and Tanaka. This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed December 15, 2018 7:15 AM EST
A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4+ T cells in the hu-PBL SCID mice

Akira Kodama1, Reiho Tanaka1, Mineki Saito1, Aftab A. Ansari3 and Yuetsu Tanaka1*

1 Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
2 Department of Microbiology, Kawasaki Medical School, Kurashiki, Japan
3 Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA

*Correspondence: Yuetsu.Tanaka, Department of Immunology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Okinawa 903-0215, Japan

Because dendritic cells (DCs) play a critical role in the regulation of adaptive immune responses, they have been ideal candidates for cell-based immunotherapy of cancers and infections in humans. Generally, monocyte-derived DCs (MDDCs) were generated from purified monocytes by multiple steps of time-consuming physical manipulations for an extended period cultivation. In this study, we developed a novel, simple and rapid method for the generation of type-1 helper T cell (Th1)-stimulating human DCs directly from bulk peripheral blood mononuclear cells (PBMCs). PBMCs were cultivated in the presence of 20 ng/ml of granulocyte-macrophage colony-stimulating factor, 20 ng/ml of interleukin-4 (IL-4) and 1,000 U/ml of interferon-γ for 24 h followed by 24 h maturation with a cytokine cocktail containing 10 ng/ml of tumor necrosis factor-α (TNF-α), 10 ng/ml of IL-1β and 1 μg/ml of prostaglandin E2. The phenotype and biological activity of these new DCs for induction of allogeneic T cell proliferation and cytokine production were comparable to those of the MDDCs. Importantly, these new DCs pulsed with inactivated HIV-1 could generate HIV-1-reactive CD4+ T cell responses in humanized mice reconstituted with autologous PBMCs from HIV-1-negative donors. This simple and quick method for generation of functional DCs will be useful for future studies on DC-mediated immunotherapies.

Keywords: dendritic cell, short-term culture, Th1-inducing DCs, anti-HIV-1 T cell response, hu-PBL-SCID

INTRODUCTION

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) which play a critical role in the regulation of the adaptive immune response through activation and polarization of naive T cells (Banchereau et al., 2000). Since small numbers of activated DCs are highly efficient in generating immune responses against infections and cancers (Moll and Berberich, 2001; Steinman and Banchereau, 2007), the DC therapy represents a new and promising immunotherapeutic approach for treatment of advanced cancers as well as for prevention of infectious diseases. Indeed, the current clinical trials with ex vivo-generated DCs (so-called DC vaccine) will yield precious information regarding their potential as vectors for immunotherapy (Gilboa, 2007; Connolly et al., 2008; Ezetelab and Thomson, 2011). However, the general protocols to generate DCs are complicated and time consuming. Moreover, since different ex vivo DC generation methods affect the DC phenotype and function (Kalantari et al., 2011), it is critical to choose appropriate method for generating functional DCs. In general, the DC precursor monocytes are purified from PBMCs by adherence (Sonnet et al., 2001), elutriation (Burger et al., 2005) or positive or negative selection using immunomagnetic beads (Babatz et al., 2003). These enriched monocytes are then induced to differentiate into DCs by 5 days-in vitro culture in medium supplemented with granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 followed by a 2-days maturation procedure (Sallusto and Lanzavecchia, 1994; Gilboa, 2007; Dauer et al., 2008). However, a lines of evidence are increasing that mature monocyte-derived DCs can be generated even after short-term cell culture for 2–3 days (Dauer et al., 2003; Jarnjak-Jankovic et al., 2007; Zhang et al., 2008; Tawab et al., 2009).

In this study, in an attempt to simplify the methods currently being used for optimal DC generation and to develop a standardized method of preparing effective myeloid DC vaccine for immunotherapies, we explored the efficacy of using unfractonated PBMCs as a source of DC precursors and short-term in vitro cell culture just for 2 days.

MATERIALS AND METHODS

REAGENTS

The media used were RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% fetal calf serum (FCS; Sigma, St. Louis, MO, USA), 100 U of penicillin per ml and 100 μg of streptomycin per ml (hereafter called RPMI medium) and Iscove’s modified Dulbecco’s medium (Lifetechologies, Grand Island,
NY, USA) supplemented with 10% FCS with the same antibiotics (hereafter called Iscove’s medium). Aldrichio-2–2 (AT-2) and low-endotoxin bovine serum albumin (BSA) was purchased from Sigma (St. Louis, MO, USA). The recombinant human cytokines used included IL-4, GM-CSF, TNF-α and IL-1β (PeproTech, London, UK). Enzyme-linked immunosorbent assay (ELISA) kits for the quantitation of human IFN-γ, human IL-4, human IL-10 and human IL-12 (detecting IL-12 p75 heterodimer) were purchased from Biolegend. The human monocyte negative isolation kits and human T cell isolation kits were purchased from Invitrogen (Carlsbad, CA, USA). The human naive CD4+ T cell isolation kit was purchased from Miltenyi Biotec (Gladbach, Germany). The V Bryant CF1M SE Cell Tracer Kit was purchased from Invitrogen.

**GENERATION OF DCs**

Human PBMCs were isolated from heparinized peripheral blood obtained from normal healthy adult volunteer donors by standard density gradient centrifugation. Cells at the interface were collected and washed three times in cold phosphate-buffered saline (PBS) containing 0.1% low-endotoxin BSA and 2 mM Na2EDTA. For select experiments, monocytes were purified from PBMCs using the CD14+ monocyte negative isolation kit (Invitrogen, Carlsbad, CA, USA). An aliquot of cells from each monocyte preparation was examined by flow cytometry and found to contain >90% CD14+ cells. To obtain immature MDDCs (iMDDCs), PBMCs (2.5 × 106 cells/ml) or the purified monocytes (5 × 105 cells/ml) were cultured in RPMI medium containing 20 ng/ml of human GM-CSF and 20 ng/ml of human IL-4 at 37°C in 24-well plates in a 5% CO2 humidified incubator for 5 days. In other experiments, iDCs were generated from either purified monocytes or whole PBMCs by cultivation in RPMI medium containing GM-CSF (20 ng/ml), IL-4 (20 ng/ml) and IL-1β (1,000 U/ml) for 1 day. These iDCs were matured by incubation in the presence of either 10 ng/ml of LPS (Sigma) or a cocktail containing 10 ng/ml of TNF-α, 10 ng/ml of IL-1β and 1 μg/ml of prostaglandin E2 (PGE2; TTP cocktail) for 1–2 days.

**FLOW CYTOMETRY**

Aliquots of the cells to be analyzed were incubated in PBS containing 0.1% BSA and 0.1% sodium azide (FACS buffer) supplemented with 2 mg/ml normal human IgG on ice for 15 min to block Fc receptors. The cell suspension was then incubated with a predetermined optimal concentration of the appropriate fluorescent dye-labeled mAbs against human cell surface markers on ice for 30 min. The fluorescent dye-labeled monoclonal antibodies (mAbs) against human cell surface molecules used included anti-CD3, anti-CD4, anti-CD8, anti-CD14, CD20, anti-CD80, anti-HLA-DR, and isotype-matched control mAbs (Beckman Coulter, Fullerton, CA, USA), and anti-CD11c, anti-CD86, and anti-CD83 (BioLegend, San Diego, CA, USA). After washing with FACS buffer, cells were fixed in 1% paraformaldehyde (PFA) containing FACS buffer. The cells were then analyzed using a human CD4+ T cell isolation kit according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA), then co-cultured with allogeneic DCs at a T:DCs ratio of 50:1 in 100 μl of RPMI medium supplemented with 20 U/ml human IL-2 in 96-well, U-bottomed plates. Cell proliferation and cytokine production were determined on day 4.

**HIV-1 PREPARATION AND INACTIVATION**

HIV-1 is a virus that only use CXCR4 as chemokine co-receptor, termed X4. The virus was harvested from Molt-4/IIB cell cultures. Batches of each HIV-1 preparation were inactivated with Aldrichio-2–2 (AT-2, Sigma) as described previously by Yoshida et al. (2003). AT-2 was removed by three successive ultracentrifugation in PBS using 100-kDa cut-off centrifugal filtration devices (Centriprep 100, Amicon, Beverly, MA, USA). Then AT-2–inactivated HIV-1 (iHIV) was purified by pelleting down the virus at 20,000 × g for 2 h three times in 0.1% BSA-PBS. The virus pellet was resuspended in 0.1% BSA-PBS, aliquoted, and stored at −80°C until use. The concentration of HIV-1 was estimated by measuring levels of HIV-1 p24 antigen with an in-house p24 ELISA kit (Tanaka et al., 2010). As previously described by Yoshida et al. (2003), activated human PBMCs incubated with an aliquot of 1 μg/ml of the AT-2–treated HIV-1 preparation failed to demonstrate the presence of any detectable infectious virions (data not shown).

**STIMULATION OF T CELLS**

Enriched populations of naive CD4+ T cells and bulk T cells with >90% purity were isolated from normal human PBMCs by using appropriate negative cell isolation kits. These T cells (4 × 106 cells/well) were first labeled with carboxy-fluorescein diacetate succinimidyl ester (CFSE) according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA), then co-cultured with allogeneic DCs at a T:DCs ratio of 50:1 in 100 μl of RPMI medium supplemented with 20 U/ml human IL-2 in 96-well, U-bottomed plates. Cell proliferation and cytokine production were determined on day 4.

In vitro infection assay

The BALB/c-rag2−/−;γc−/− mice lacking T cells, B cells and natural killer (NK) cells (Rag2−/−;γc−/− mice; Traggiai et al., 2004) were used in this study. The mice were kept in the specific-pathogen-free and F3 animal facilities of the Laboratory Animal Center, University of the Ryukyus. The protocols for the care and use of mice engrafted with human PBMCs and allogeneic DCs sensitized with inactivated HIV-1 or ovalbumin (OVA) were approved by the committee on animal research of the University of the Ryukyus prior to initiation of the study. Matured DCs (3 × 105 cells) pulsed with either AT-2–inactivated HIV-1 (40 ng of p24) or 100 μg of OVA in 100 μl of RPMI medium for 2 h at 37°C were mixed with autologous fresh PBMCs (3 × 106 cells) in a final volume of 100 μl in serum-free RPMI medium, and were directly injected into the spleen of Rag2−/− mice as previously described by Yoshida et al. (2003). One week later, the same number of DCs pulsed with the same antigens were inoculated again into the spleen. One week later, mice were sacrificed, blood was collected by cardiocentrifugation. Cells at the interface were collected and washed three times in cold phosphate-buffered saline (PBS) containing 0.1% low-endotoxin bovine serum albumin (BSA-PBS), aliquoted, and stored at −80°C until use. The concentration of HIV-1 was estimated by measuring levels of HIV-1 p24 antigen with an in-house p24 ELISA kit (Tanaka et al., 2010). As previously described by Yoshida et al. (2003), activated human PBMCs incubated with an aliquot of 1 μg/ml of the AT-2–treated HIV-1 preparation failed to demonstrate the presence of any detectable infectious virions (data not shown).

**hu-PBL-SCID MICE**

The BALB/c-rag2−/−;γc−/− mice lacking T cells, B cells and natural killer (NK) cells (Rag2−/−;γc−/− mice; Traggiai et al., 2004) were used in this study. The mice were kept in the specific-pathogen-free and F3 animal facilities of the Laboratory Animal Center, University of the Ryukyus. The protocols for the care and use of mice engrafted with human PBMCs and allogeneic DCs sensitized with inactivated HIV-1 or ovalbumin (OVA) were approved by the committee on animal research of the University of the Ryukyus prior to initiation of the study. Matured DCs (3 × 105 cells) pulsed with either AT-2–inactivated HIV-1 (40 ng of p24) or 100 μg of OVA in 100 μl of RPMI medium for 2 h at 37°C were mixed with autologous fresh PBMCs (3 × 106 cells) in a final volume of 100 μl in serum-free RPMI medium, and were directly injected into the spleen of Rag2−/− mice as previously described by Yoshida et al. (2003). One week later, the same number of DCs pulsed with the same antigens were inoculated again into the spleen. One week later, mice were sacrificed, blood was collected by cardiocentrifugation. Cells at the interface were collected and washed three times in cold phosphate-buffered saline (PBS) containing 0.1% low-endotoxin bovine serum albumin (BSA-PBS), aliquoted, and stored at −80°C until use. The concentration of HIV-1 was estimated by measuring levels of HIV-1 p24 antigen with an in-house p24 ELISA kit (Tanaka et al., 2010). As previously described by Yoshida et al. (2003), activated human PBMCs incubated with an aliquot of 1 μg/ml of the AT-2–treated HIV-1 preparation failed to demonstrate the presence of any detectable infectious virions (data not shown).

**P24 DETECTION**

The concentration of HIV-1 was estimated by measuring levels of HIV-1 p24 antigen with an in-house p24 ELISA kit (Tanaka et al., 2010). As previously described by Yoshida et al. (2003), activated human PBMCs incubated with an aliquot of 1 μg/ml of the AT-2–treated HIV-1 preparation failed to demonstrate the presence of any detectable infectious virions (data not shown).

**P24 DETECTION**

The concentration of HIV-1 was estimated by measuring levels of HIV-1 p24 antigen with an in-house p24 ELISA kit (Tanaka et al., 2010). As previously described by Yoshida et al. (2003), activated human PBMCs incubated with an aliquot of 1 μg/ml of the AT-2–treated HIV-1 preparation failed to demonstrate the presence of any detectable infectious virions (data not shown).
of human IFN-γ or IL-4 produced in the culture supernatants was determined with ELISA kits.

**STATISTICAL ANALYSIS**

Data were analyzed by Student’s t test with the Prism software (GraphPad Software Inc., San Diego, CA, USA).

**RESULTS**

**GENERATION OF MYELOID MATURE DCs DIRECTLY FROM PBMCs WITHIN 2 DAYS**

In order to reduce the cost, labor and any loss of potential precursors from PBMCs, we have previously established a novel culture method for generating functional human DCs from unfractionated PBMC in which whole PBMCs were cultured in the presence of IL-4 and GM-CSF for 5 days followed by a 2-day maturation in media containing poly I:C and IL-1β (Kodama et al., 2010). However, there were considerable lot variations in commercial poly:IC in the DC-maturation activity (data not shown). Therefore, we tested a previously reported maturation cytokine cocktail containing TNF-α, IL-1β, IL-6 and PGE2 (Jonuleit et al., 1997). In a preliminary study, we found that IL-6 was not necessary to mature DCs from purified monocytes in the present cell culture conditions, probably due to the use of serum-containing media. Thus, we used a cytokine cocktail (TIP) instead of poly I:C for maturation.

![Image of flow cytometry data](https://example.com/flow_cytometry.png)

**FIGURE 1** | Generation of functional human myeloid DCs directly from PBMCs in vitro within 2 days. MDDCs generated purified monocytes for 7 days (7-day-DC/Mo) or whole PBMCs cultured in medium containing GM-CSF, IL-4 and IFN-γ (2-day-DC/PBMC), either non-treated or treated with the maturation cocktail containing TNF-α, IL-1β and PGE2 (TIP) were examined for the expression of mature DC markers by a flow cytometry. Cells were stained with antibodies to CD11c, CD14, CD83, CD86, and analyzed on a subpopulation gated for FSC < 75%, SSC < 116% and CD11c+ . The percentages of the positive cells in the gated population were shown in the dot plots. Data shown are representative of three independent experiments using blood from three different donors.

“fmicb-04-00292” — 2013/9/26 — 14:32 — page 3 — #3
containing 10 ng/ml of TNF-α, 10 ng/ml of IL-1β and 1 μg/ml of PGE2 (hereafter called TIP cocktail) throughout the present study.

Based on our previous report that monocytes can be differentiated into mature DCs within 2 days (Zhang et al., 2008), we tested whether Th1-inducing DCs could be generated from unfractionated PBMCs. PBMCs (2.5 × 10⁶ cells/ml) were cultured in RPMI medium containing GM-CSF (20 ng/ml), IL-4 (20 ng/ml) and IFN-β (1,000 U/ml) for 1 day followed by additional 1 day cultivation in the presence or absence of the TIP cocktail. The phenotypes of CD11c⁺ large cells in these 2-day PBMC cultures were compared with those of MDDCs derived from purified monocyte for 7 days (7-day-DC/Mo, Figure 1). The proportion of CD14⁺CD16⁻ and CD14⁻CD16⁺ cells in the 2-day DC/PBMC culture was 20–25% of total viable cells depending on donors and these cells expressed CD11c (data not shown). After maturation with the TIP cocktail, similar to the 7-day-DC/Mo, the large CD11c⁺ cells in the 2-day PBMC cultures became CD14⁻CD16⁻ and CD14⁺CD16⁺, a typical marker of matured myeloid DCs (Uchialina et al., 1997). The other viable cell populations in the 2-day PBMC cultures were CD3⁺ T cells (54.0–59.2%), CD56⁺ NK cells (8.4–9.3%) and CD19⁺ B cells (6.3–8.6%; n = 3). These data showed that the present culture method was applicable to generate mature DCs from bulk PBMCs within 2 days (2-day-DC/PBMC).

Then we tested cytokine production by these 2-day-DC/PBMC. Interestingly, in contrast to the DCs matured in the presence of LPS, the production of IL-12 and IL-10 by the TIP matured 2-day-DC/P was minimum (Figure 2). To investigate whether the 2-day-DC/PBMC were immunologically functional, we examined their ability to stimulate allogeneic T cell proliferation (Figure 3A). Then we quantitated the levels of IFN-γ and IL-4 in the culture supernatants from allogeneic CD4⁺ T cells co-cultured with various DCs. As shown in Figure 3B, among the four DC preparations including the 7-day-DC/Mo, 7-day-DCs from PBMCs (7-day-DC/PBMC), 2-day-DCs from monocytes (2-day-DC/Mo) and 2-day-DC/PBMC, the 2-day-DC/PBMC were most potent in induction of IFN-γ production. The bulk 2-day-DC/PBMC alone did not produce detectable IFN-γ (<20 pg/ml) in the present culture conditions (data not shown). The levels of IL-4 and IL-10 were below detection (<5 pg/ml) in all the samples tested (data not shown). These results indicated that the 2-day-DC/PBMC had a potential to induce Th1 response.

**INDUCTION OF HIV-1-REACTIVE HUMAN CD4⁺ T CELL RESPONSES IN hu-PBL-SCID MICE**

Finally, we examined whether the short-term generated 2-day-DC/PBMC could induce HIV-1-reactive immune responses in vivo in comparison to MDDCs (7-day-DC/Mo) using our hu-PBL-SCID mouse model (Yoshida et al., 2003). SCID mice were intrasplenically transplanted with DCs loaded with AT-2-inactivated HIV-1 together with autologous fresh PBMCs. On day 7, these mice were received an intraperitoneal booster injection with similarly prepared antigen-pulsed DCs. Seven days after the booster injection, mice were sacrificed and examined for antigen-specific human immune responses. Figure 4 showed that after in vitro re-stimulation with autologous APCs pulsed with inactivated HIV-1, enriched human CD4⁺ T cells from two out of three mice immunized with MDDCs (7-day-DC/Mo) pulsed with HIV-1 and those from three out of four mice immunized with 2-day-DC/PBMC pulsed with HIV-1 produced IFN-γ in antigen-dependent way, indicating that the 2-day-DC/PBMC could induce HIV-1 antigen-reactive human T responses in vivo as potent as MDDCs. In the re-stimulated culture supernatants, no IL-4 or IL-10 was detected (<5 pg/ml) using ELISA (data not shown). In addition, no detectable antibodies against HIV-1 were detected.

**FIGURE 2 | Production of cytokines by the 2-day-DC/PBMC.** The levels of IL-12 (Bioactive p70 heterodimer) and IL-10 in the supernatants from MDDCs (7-d-DC/M) or 2-day-DC/PBMC either non-matured (iM) or matured with LPS or the TIP cocktail were determined by ELISA. Data are mean ± SD of triplicate cultures. *P < 0.05, **P < 0.001. Data shown are representative of three independent experiments using blood from two different donors.
as determined by using a commercial Western blot assay kit in plasma samples from all the DCs-HIV-1-immunized mice (data not shown).

Altogether, these results demonstrated that human myeloid DCs directly generated from PBMCs by the present short-term cultivation method were potent in induction of functional Th1 responses both in vitro and in vivo.

**DISCUSSION**

In the present study, we have developed a novel, simple and rapid protocol for generating Th1-stimulating human myeloid DCs directly from unfractionated PBMCs. These 2-day-DC/PBMC were potent in both stimulating allogeneic T cells in vitro and inducing HIV-1-reactive Th1 responses in hu-PBL-SCID mice.

The use of whole PBMCs as DC precursors might reduce any loss of monocytes in the step of purification by adherence (Jonuleit et al., 2001), clariation (Berger et al., 2005) or positive or negative selection using immunomagnetic beads (Babatz et al., 2003).

One possible concern on using whole PBMCs was that the non-monocyte cells, such as T, B or NK cells, in the PBMCs might interfere with differentiation and function of DCs. However, in the present study there was no obvious difference in DC maturation and function between in PBMC and purified monocyte cultures.

For the final maturation, we used a cytokine cocktail containing TNF-α and IL-1β and PGE2 (TIP cocktail). Simultaneous use of these three reagents in TIP was essential for maturation of DCs since use of the reagents either in single or in two combinations failed to mature DCs (data not shown). In general, IL-6 that is included in the maturation cytokine cocktail TNF-α and IL-1β and PGE2 to mature DCs was not necessary in the present culture conditions. The reason remains to be studied, but it is possible that IL-6 is required in serum-free culture conditions. The present 2-day-DC/PBMC matured by TIP produced lower IL-12 than those matured by LPS. Low levels production of IL-12 might be ascribed to the use of PGE2 that inhibits bioactive IL-12 heterodimer production (Kalinski et al., 2001; Kalim and Gonnert, 2013). Despite of the low level production of IL-12, the TIP-matured 2-day-DC/PBMC were potent in stimulating IFN-γ, but not IL-4 or IL-10, production by allogeneic T cells. The reason for higher potentials of 2-day-DC/PBMC to induce Th1 cells than MDDCs remains to be clarified. It is speculated that natural DCs contained in the 2-day-PBMC-derived DCs might enhance the activation. Indeed, 2-day-DC/PBMC culture generated from CD4+ cell-depleted PBMCs were able to stimulate allogeneic CD4+ T cells to a lesser extent (data not shown). However, we cannot clearly determine if the stimulation was mediated by remaining monocytes. Further study is required to solve this issue. Importantly, as the previous study (Yoshida et al., 2003), the present study showed the induction of primary HIV-1-specific human CD4+ T cell immune responses in hu-PBL-SCID mice by DC-based immunization, demonstrating that the present 2-day-PBMC-derived DCs might have a potential for clinical use in DC-based immunization in humans against HIV-1. It was of interest that the levels of IFN-γ production were higher in CD4+ T cells immunized with 7-day-DC/Mo. It is possible that 2-day-DC/PBMC could live longer than 7-day-DC/Mo in vivo to stimulate antigen-specific CD4+ T cells. In addition, because myeloid DCs are susceptible to HIV-1 infection (Knight et al., 1999), the use of these IFN-β-treated DCs will be beneficial for HIV-1-infected individuals. In conclusion, the present study provided a new method to generate functional human myeloid DCs directly from PBMCs in a short-term culture period. These DCs will be useful for studies exploring potentials of DC-based immunization for not only infectious diseases but also cancers in vitro and in vivo.

**ACKNOWLEDGMENTS**

This work was supported by the Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
REFERENCES

AUTHOR CONTRIBUTIONS
Akira Kodama designed and performed the experiments, analyzed the data and wrote the paper. Reiko Tanaka and Mineki Saito performed the experiments, analyzed the data and wrote the paper.

Aftab A. Ansari participated in the design of the study and helped to draft the manuscript. Yuetsu Tanaka designed and supervised the research, performed experiments and wrote the paper. All authors checked the final version of this manuscript.

FIGURE 4: Functional activity of the 2-day DCs in in-PSL-SCID mice. Fresh autologous PBMCs from normal human donors were transferred into fresh, naive mice at the day 0.7-day (DC-Mo) or 2 days (DC-PBMC) pulsed with no antigen or antigens of dendritic cells (DCs) for 2 days at 37°C. IFN-γ levels produced in the culture supernatants were measured by ELISA. Data show mean ± SD of triplicate cultures. *P < 0.05, **P < 0.01, ***P < 0.001. Data shown are representative of three independent experiments using blood from two different donors.

Frontiers in Microbiology | Virolology September 2013 | Volume 4 | Article 292 | #6


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 25 June 2013; accepted: 10 September 2013; published online: 27 September 2013.

Copyright © 2013 Kodama, Tanaka, Saito, Ansari and Tanaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.